

Vasilios Tzilas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5760460/publications.pdf>

Version: 2024-02-01

55
papers

879
citations

516215

16
h-index

500791

28
g-index

56
all docs

56
docs citations

56
times ranked

1245
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Effectiveness of Mycophenolate Mofetil in Interstitial Lung Diseases: Insights from a Machine Learning Radiographic Model. <i>Respiration</i> , 2022, 101, 262-271.	1.2	8
2	Differential immunohistochemical expression of hTERT in lung cancer patients with and without idiopathic pulmonary fibrosis. <i>Pulmonology</i> , 2022, , .	1.0	2
3	2022 update on clinical practice guidelines for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. <i>Lancet Respiratory Medicine</i> ,the, 2022, 10, 729-731.	5.2	13
4	Diagnostic Confidence and Prognosis in Fibrotic Hypersensitivity Pneumonitis: Classification Is Fundamental. <i>Respiration</i> , 2021, 100, 1-3.	1.2	0
5	Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis. <i>Respiratory Research</i> , 2021, 22, 140.	1.4	37
6	Reversed halo sign in radiation induced organizing pneumonia: natural course of the underlying pathophysiology. <i>Pulmonology</i> , 2021, 27, 460-464.	1.0	3
7	Early COVID-19 lockdown in Greece and idiopathic pulmonary fibrosis: a beneficial "impact" beyond any expectation. <i>European Respiratory Journal</i> , 2021, 57, 2003111.	3.1	11
8	Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease: In Search for Evidence-Based Medicine. <i>Respiration</i> , 2020, 99, 930-931.	1.2	0
9	Immune Checkpoint Inhibitor-Related Pneumonitis. <i>Respiration</i> , 2020, 99, 932-942.	1.2	30
10	Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study. <i>ERJ Open Research</i> , 2020, 6, 00152-2020.	1.1	15
11	Radiological honeycombing: pitfalls in idiopathic pulmonary fibrosis diagnosis. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 1107-1116.	1.0	3
12	Management of Patients with Interstitial Lung Disease in the Midst of the COVID-19 Pandemic. <i>Respiration</i> , 2020, 99, 625-627.	1.2	14
13	Hypersensitivity pneumonitis: the first diagnostic guidelines. <i>Lancet Respiratory Medicine</i> ,the, 2020, 8, 955-957.	5.2	7
14	A 77-Year-Old Woman With Sjogren Syndrome Experiencing Progressive Dyspnea on Exertion and Nonproductive Cough. <i>Chest</i> , 2020, 158, e117-e121.	0.4	1
15	Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study. <i>ERJ Open Research</i> , 2020, 6, 00172-2019.	1.1	37
16	Cystic lung disease in Birt-Hogg-Dub� syndrome. A case series. <i>Respiratory Medicine Case Reports</i> , 2020, 30, 101081.	0.2	1
17	Impact of Depression on Patients With Idiopathic Pulmonary Fibrosis. <i>Frontiers in Medicine</i> , 2020, 7, 29.	1.2	18
18	Intravenous Immunoglobulin for the Treatment of COVID-19: A Promising Tool. <i>Respiration</i> , 2020, 99, 1087-1089.	1.2	21

#	ARTICLE	IF	CITATIONS
19	Influence of inhalation device, active substance, and drug formulation on the compliance of patients with obstructive pulmonary diseases. A physiciansâ€™ perspective. Pulmonology, 2020, , .	1.0	0
20	Update on COVID-19: A teleconference with the Paediatric Virology Study Group (Review). Experimental and Therapeutic Medicine, 2020, 20, 293.	0.8	0
21	Update on COVIDâ€™19: A teleconference with the Paediatric Virology Study Group (Review). Experimental and Therapeutic Medicine, 2020, 20, 1-1.	0.8	0
22	Diagnostic value of BAL lymphocytosis in patients with indeterminate for usual interstitial pneumonia imaging pattern. European Respiratory Journal, 2019, 54, 1901144.	3.1	27
23	A 63-Year-Old Woman With Pulmonary Micronodules and Chronic Cough. Chest, 2019, 156, e47-e50.	0.4	0
24	Vitamin D prevents experimental lung fibrosis and predicts survival in patients with idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2019, 55, 17-24.	1.1	62
25	Common Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung Cancer. Chest, 2019, 156, 383-391.	0.4	84
26	Safety and Efficacy of Early and Long-Term Use of Pirfenidone in Idiopathic Pulmonary Fibrosis. Respiration, 2019, 98, 16-18.	1.2	0
27	Interstitial lung abnormalities: ignotum per ignotius. Lancet Respiratory Medicine,the, 2019, 7, 376-378.	5.2	7
28	Interstitial Lung Abnormalities. Chest, 2019, 156, 1037-1038.	0.4	6
29	Lung complications of neuromuscular diseases. , 2019, , 278-295.		3
30	Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece. Pulmonary Pharmacology and Therapeutics, 2018, 49, 61-66.	1.1	49
31	Patients with IPF and lung cancer: diagnosis and management. Lancet Respiratory Medicine,the, 2018, 6, 86-88.	5.2	67
32	Taking a giant step in the diagnosis of idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2018, 6, 82-84.	5.2	10
33	Crazy paving pattern as a rare radiological manifestation of peripheral T-cell lymphoma (PTCL) with lung involvement: A case report. Respiratory Medicine Case Reports, 2018, 25, 253-256.	0.2	4
34	Diagnostic guidelines for IPF: when art meets science. Lancet Respiratory Medicine,the, 2018, 6, 812-814.	5.2	5
35	Metformin in Idiopathic Pulmonary Fibrosis â€œSeeking the Holy-Grail through Drug-Repositioningâ€. Respiration, 2018, 96, 305-307.	1.2	5
36	Prognosis of Interstitial Lung Disease Associated with Anti-Aminoacyl-tRNA Synthetase Antibodies: Look in the Middle. Respiration, 2018, 96, 207-209.	1.2	2

#	ARTICLE	IF	CITATIONS
37	Guidelines for Idiopathic Pulmonary Fibrosis: Everything Flows. <i>Respiration</i> , 2017, 93, 401-403.	1.2	3
38	Lung cancer in patients with idiopathic pulmonary fibrosis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 45, 1-10.	1.1	129
39	Diagnostic and prognostic challenges in Idiopathic Pulmonary Fibrosis: A patient's 'Q and A' approach. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 42, 21-24.	1.1	18
40	Dissecting Survival Pathways in Lung Cancer, Fibrosis and Emphysema: 'The Four Horses of the Apocalypse' <i>Respiration</i> , 2017, 94, 239-241.	1.2	0
41	Metsovo Lung: A Story of Episteme, Techne, and Phronesis. <i>Respiration</i> , 2017, 94, 491-492.	1.2	0
42	Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 46, 48-53.	1.1	41
43	Pirfenidone in Idiopathic Pulmonary Fibrosis 'RECAP-ulating Safety into the Real World' <i>Respiration</i> , 2017, 94, 405-407.	1.2	4
44	Diagnosis of Idiopathic Pulmonary Fibrosis 'Pragmatic Challenges in Clinical Practice' <i>Frontiers in Medicine</i> , 2017, 4, 151.	1.2	14
45	Longitudinal 'Real-World' Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece. <i>Frontiers in Medicine</i> , 2017, 4, 213.	1.2	43
46	Metabolic Disorders in Chronic Lung Diseases. <i>Frontiers in Medicine</i> , 2017, 4, 246.	1.2	25
47	Cardiopulmonary Exercise Testing in Systemic Sclerosis: 'Ars longa, vita brevis'. <i>Respiration</i> , 2016, 91, 202-203.	1.2	2
48	Idiopathic Pulmonary Fibrosis and Emphysema: Between Scylla and Charybdis. <i>Respiration</i> , 2016, 92, 215-217.	1.2	2
49	Usual interstitial pneumonia pattern in the diagnosis of idiopathic pulmonary fibrosis?. <i>Lancet Respiratory Medicine</i> , 2016, 4, 770-772.	5.2	8
50	The Six-Minute Stepper Test: Solvitur ambulando. <i>Respiration</i> , 2016, 91, 469-470.	1.2	2
51	Combined Pulmonary Fibrosis and Emphysema, a clinical review. <i>COPD Research and Practice</i> , 2016, 2, .	0.7	5
52	Inherent weaknesses of the current ICD coding system regarding idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2015, 45, 1194-1196.	3.1	8
53	Persistent left superior vena cava mistaken for nodal metastasis: a case report. <i>Journal of Medical Case Reports</i> , 2010, 4, 174.	0.4	4
54	Prognostic Factors in Idiopathic Pulmonary Fibrosis. <i>American Journal of the Medical Sciences</i> , 2009, 338, 481-485.	0.4	16

#	ARTICLE	IF	CITATIONS
55	Als Hypersensitivit�tspneumonitis maskiertes Antisynthetase-Syndrom. Karger Kompass Pneumologie, 0, 1-9.	0.0	0